All dates for this event occur in the past.

110-120 CBEC
151 W Woodruff Ave
Columbus, OH 43210
United States

This Lecture has been postponed to a later date.

Lessons in Drug Delivery and Translation: The Value of The Chemical Engineering Perspective

We are in an era of unprecedented technological and scientific advances that promise to transform human health and society.   In this talk I will try to summarize my experience regarding the basic steps in drug discovery in academy and translation to the commercial world.   The many challenges and opportunities in therapeutics and the value of a chemical engineering education will be discussed.

George Georgiou is the Dula D. Cockrell Centennial Chair and Professor at UT Austin, Dep. of Chemical Engineering and Molecular Biosciences. He has authored >280 publications and is co-inventor of >150 issued and pending US patents, comprising 28 distinct technology suites that have been licensed to 32 pharma & biotech companies.  Dr. Georgiou is an elected member of the National Academy of Engineering (2005), National Academy of Medicine (2011), National Academy of Inventors (2015) and the American Academy of Arts and Sciences (2015). He was awarded the AICHE Professional Progress award in 2004 and the AICHE William Walker award in 2019.   In 2013 Georgiou was selected as one of the top 20 Translational Researchers by Nature Biotechnology. 

Dr. Georgiou founded GGMJD in 1999 (acquired by Maxygen in 2000), Aeglea Biotherapeutics in 2013 (NSDQ: AGLE) and Ikena Oncology (NSDQ: IKNA) in 2016 and served on the Board of Directors of both AGLE and IKNA. 

Dr. Georgiou’s research is focused on: (i) the molecular level understanding of human adaptive immunity in infectious diseases and in autoimmunity; (ii) the discovery/preclinical development of protein therapeutics and (iii) the biology of Fc receptors and the engineering of therapeutic antibodies with improved effector functions. 

Notably, he is co-inventor of 5 protein therapeutics approved or in clinical/late-stage preclinical evaluation: olbitoxaximab, pegzilarginase (under EMA review), AGLE-177 (pegtaviliase, phase I/II), IK-412 and cyst(e)inease (AGLE-325).